Despite the rarity of RDEB, larger cohort studies will be needed to confirm our conclusions and address existing knowledge gaps, including determining the prevalence of PD-1 and EGFR tumor expression in RDEB-cSCCs and correlating increased expression with response to immunotherapy or anti-EGFR therapy, respectively. This evidence concerns the gene EGFR and neoplasm.